Macrocyclic peptidomimetic protease inhibitor and use thereof
US-2024327458-A1 · Oct 3, 2024 · US
Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US9624229B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9624229-B2 |
| Application number | US-201414243579-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 2, 2014 |
| Priority date | Feb 15, 2008 |
| Publication date | Apr 18, 2017 |
| Grant date | Apr 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R 1 , R 2 , R 3 , R 4 and R 5 are disclosed herein, or a pharmaceutically acceptable salt.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating, but not preventing, a disease or condition associated with JAK2 activity in a mammal, wherein the method comprises administering to the mammal a therapeutically effective amount of 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3-methyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof, and the disease or condition is polycythemia vera disorder, essential thrombocythemia disorder or primary myelofibrosis. 2. A method of treating, but not preventing, a disease or condition associated with JAK2 activity in a mammal, wherein the method comprises administering to the mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3-methyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof, and the disease or condition is polycythemia vera disorder, essential thrombocythemia disorder or primary myelofibrosis. 3. The method of claim 1 wherein the disease or condition is polycythemia vera disorder. 4. The method of claim 1 wherein the disease or condition is essential thrombocythemia disorder. 5. The method of claim 1 wherein the disease or condition is primary myelofibrosis. 6. The method of claim 2 wherein the disease or condition is polycythemia vera disorder. 7. The method of claim 2 wherein the disease or condition is essential thrombocythemia disorder. 8. The method of claim 2 wherein the disease or condition is primary myelofibrosis.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
specific for leukemia · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9624229B2 cover?
- This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R 1 , R 2 , R 3 , R 4 and R 5 are disclosed herein, or a pharmaceutically acceptable salt.
- Who is the assignee on this patent?
- Rigel Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).